Showing 5461-5470 of 5909 results for "".
- Iveric bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapyhttps://modernod.com/news/iveric-bio-announces-successful-advancement-of-lca10-minigene-program-and-expansion-of-orphan-gene-therapy/2476762/Iveric bio announced that the company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation independent novel adeno-associated virus (AAV) gene therapy product candidates
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur
- B+L Introduces FreeFlow Infusion System and 23-Gauge Bi-Blade Dual Port Vitrectomy Cutterhttps://modernod.com/news/bausch-lomb-introduces-freeflow-infusion-system-for-retina-surgery/2476761/Bausch + Lomb announced the launch of the FreeFlow infusion system for retina surgery and the 23-gauge Bi-Blade dual port vitrectomy cutter for the Stellaris Elite vision enhancement system. The FreeFlow infusion system allows for higher level of infusion flow compared to previous generati
- Notal Vision Diagnostic Clinic Reports Completion of 6 Million ForeseeHome AMD Home-Monitoring Testshttps://modernod.com/news/notal-vision-diagnostic-clinic-reports-completion-of-6-million-foreseehome-amd-home-monitoring-tests/2476750/Notal Vision announced the completion of 6 million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD, according to a company news release. ForeseeHo
- Nidek Launches LPM Low Power Mode for YLC-500 Vixihttps://modernod.com/news/nidek-launches-lpm-low-power-mode-for-ylc-500-vixi/2476744/Nidek has announced the launch of LPM optional software, a low power mode for the YLC-500 Vixi laser photocoagulator. LPM delivers a therapeutic effect to the retina by decreasing the laser power during photocoagulati
- Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.
- FDA Does Not Approve Bausch Health, Eton’s Pharma’s EM-100 for Allergic Conjunctivitishttps://modernod.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/Eton Pharmaceuticals on Friday said that partner Bausch Health Companies has received a complete response letter from the FDA for its filing seeking approval of the investigational therapy EM-100 to treat ocular itching associated with allergic conjunctivitis. “We
- Prism Vision Group Announces Launch of New Brandhttps://modernod.com/news/prism-vision-group-announces-launch-of-new-brand/2476726/Prism Vision Group, an ophthalmology administrative services care provider organization, was officially launched. The new entity is led by Steven Madreperla, MD, PhD, a practicing ophthalmologist and one of the founding partners of NJRetina, a specialty retina practice with roots that reac
- US Scraps Proposal to Curb Drug Rebates Paid to Pharmacy Benefit Managershttps://modernod.com/news/us-scraps-proposal-to-curb-drug-rebates-paid-to-pharmacy-benefit-managers/2476729/The US government pulled the plug on plans designed to reduce drug prices by limiting rebates paid by drugmakers to pharmacy benefit managers (PBMs). White House spokesman Judd Deere said on Thursday that “based on careful analysis and thorough consideration, the President has decided to wi
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o